Allergy Therapeutics plc has been mentioned in a Form 8.5 (EPT/RI) disclosure by Panmure Gordon (UK) Limited. The disclosure states that Panmure Gordon (UK) Limited, as an exempt principal trader, has made purchases and sales of Allergy Therapeutics' 0.1p ordinary shares. The purchases involved 100,000 securities at a highest price per unit of 0.0241 and a lowest price per unit of 0.023. The sales involved 197,536 securities at a highest price per unit of 0.02525 and a lowest price per unit of 0.024. No cash-settled derivative transactions or stock-settled derivative transactions were reported. No indemnity or option arrangements, agreements, or understandings were disclosed. The disclosure was made on September 25, 2023, and the contact person for further information is Freddie Wooding at +44 (0)20 7886 2969.